1 - We aim to close the loop between high-dimensional, biological profiling of compounds and rapidly learning how to drive the compound series’ evolution to higher potency, lower risk and better kinetics. This is a huge and critical component of the overall vision of industrializing drug discovery. In practice we are dedicating major efforts into ML-guided SAR and how automated synthesis integrates into this plan is part of our roadmap.

2,3 - given the highly custom nature of the automation systems we have built, and the need for ultra-high control over experimental precision, we have relationships with several automation experts in this space. As far as partnerships in this space are concerned, we can’t comment on specific business development plans or transactions until we announce them publicly. What I can say is that we recognize the work it has taken over the last decade to map and navigate biology, and we believe there are many other teams and technologies that have been developing in parallel and we’re always exploring options to bring in additional capabilities that may accelerate our mission.

4 - The “Recursion 101” video we released in October of 2022 has some of the most current footage of our automation labs — if you haven’t seen the video, we (selfishly) think it’s worth the watch. We have also released “Recursion's Mapping & Navigating Demonstration” which shows footage of our laboratories.